Skip Navigation

European Heart Journal 2000 21(6):438-445; doi:10.1053/euhj.1999.1949
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (35)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Balfour, D
Right arrow Articles by Keil, U
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balfour, D
Right arrow Articles by Keil, U
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Working Group Report

Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report

D Balfoura, N Benowitzb,c, K Fagerströmd, M Kunzee and U Keilf,f1

a Department of Pharmacology and Neuroscience, University of Dundee Medical School, Dundee, Scotland, U.K.
b Clinical Pharmacology Unit of the Medical Service, San Francisco General Hospital Medical Center, San Francisco, U.S.A.
c Departments of Medicine, Psychiatry and Pharmacy, University of California, San Francisco, U.S.A.
d Fagerström Consulting, Berga alle 1, S252 25, Helsingborg, Sweden
e Institute of Social Medicine, University of Vienna, Vienna, Austria
f Institute of Epidemiology and Social Medicine, University of Muenster, Germany

revised September 13, 1999; accepted September 15, 1999

Abstract

Tobacco use is a global health care problem. Repetitive exposure to nicotine produces neuroadaptation resulting in nicotine dependence. Cigarette smoking is particularly addictive due to the repeated delivery of bolus doses of nicotine to the bloodstream. Although compulsive tobacco use is sustained by nicotine addiction, it is the toxic combustion products in tobacco smoke such as carbon monoxide and oxidant gases that adversely affect the cardiovascular system. Smoking cessation produces significant health benefits and is a very cost-effective intervention. Evidence that nicotine is the addictive component of tobacco provides the rationale for using nicotine replacement therapy to aid cessation. Nicotine replacement therapy doubles successful smoking cessation rates and evidence-based guidelines for the treatment of tobacco addiction recommend routine use of nicotine replacement therapy, particularly in heavily dependent smokers. Success rates of up to 40% can be achieved in specialist clinics. Despite early concerns regarding the safety of nicotine replacement therapy in smokers with heart disease, it is now clear that the health risks of using nicotine replacement therapy to assist such patients to stop, or significantly reduce, smoking far outweigh any treatment-related risks.

Key Words: Tobacco dependence, smoking cessation, nicotine replacement therapy

f1 Correspondence: Ulrich Keil, Institute of Epidemiology and Social Medicine, Medical Faculty, University of Muenster, Domagkstrasse 3, 48129 Muenster, Germany.

References

  1. Pyörälä, K, DeBacker, G, Graham, I, Poole-Wilson, P, Wood, D, Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension, Eur Heart J, 1994, 15, 1300, 31, Atherosclerosis, 1994, 110, 121, 61
  2. Eur Heart J. 1997;18:1569–1582[Abstract/Free Full Text]
  3. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on Coronary Prevention. Eur Heart J. 1998;19:1434–1503[Free Full Text]
  4. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet. 1992;339:1268–1278[CrossRef][Web of Science][Medline]
  5. Benowitz NL. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol. 1996;36:597–613[CrossRef][Web of Science][Medline]
  6. International statistical classification of diseases and related health problems (ICD-10). Geneva: World Health Organization; 1992.
  7. Murray RP, Bailey WC, Daniels K. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest. 1996;109:438–445[Medline]
  8. Mahmarian JJ, Moye LA, Nasser GA. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol. 1997;30:125–130[Abstract]
  9. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: Implications for nicotine replacement therapy. J Am Coll Cardiol. 1997;29:1422–1431[Abstract]
  10. Balfour DJ, Fagerström KO. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther. 1996;72:51–81[CrossRef][Web of Science][Medline]
  11. Diagnostic and Statistical Manual of Mental Disorders. Washington: American Psychiatric Association; 1994.
  12. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86:1119–1127[CrossRef][Web of Science][Medline]
  13. Kunze U, Schmeiser-Rieder A, Schoberberger R. European Medical Association Smoking or Health (EMASH)— consensus paper. Soz Präventivmed. 1998;43:167–172[CrossRef][Web of Science][Medline]
  14. Fagerström KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerström Tolerance Questionnaire. J Behav Med. 1989;12:159–182[CrossRef][Web of Science][Medline]
  15. Wilhelmsen L. Coronary heart disease: Epidemiology of smoking and intervention studies of smoking. Am Heart J. 1988;115:242–249[CrossRef][Web of Science][Medline]
  16. Rivers JT, White HD, Cross DB, Williams BF, Norris RM. Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking. J Am Coll Cardiol. 1990;16:340–348[Abstract]
  17. Parrott S, Godfrey C, Raw M, West R, McNeill A. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. The case for smoking cessation. Thorax. 1998;53:S4–S10
  18. Tengs TO, Adams ME, Pilskin JS. Five hundred life saving interventions and their cost effectiveness. Risk Anal. 1995;15:369–390[CrossRef][Web of Science][Medline]
  19. Fiore, MC, Bailey, WC, Cohen, SJ, Smoking cessation, Rockville, MD, US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 96-0692
  20. Winniford MD, Jansen DE, Reynolds GA, Apprill P, Black WH, Hillis LD. Cigarette smoking-induced coronary vasoconstriction in atherosclerotic coronary artery disease and prevention by calcium antagonists and nitroglycerin. Am J Cardiol. 1987;59:203–207[CrossRef][Web of Science][Medline]
  21. Zevin S, Jacob P III, Benowitz NL. Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clin Pharmacol Ther. 1998;64:87–95[CrossRef][Web of Science][Medline]
  22. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997;336:1276–1282[Abstract/Free Full Text]
  23. Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q. Nicotine effects on eicosanoid formation and hemostatic function: Comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol. 1993;22:1159–1167[Abstract]
  24. Joseph AM, Norman SM, Ferry LH. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335:1792–1798[Abstract/Free Full Text]
  25. Clarke PBS. Dopaminergic mechanisms in the locomotor stimulant effects of nicotine. Biochem Pharmacol. 1990;40:1427–1432[CrossRef][Web of Science][Medline]
  26. Corrigall WA, Coen KM. Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology. 1989;99:473–478[CrossRef][Medline]
  27. Wise RA, Bozarth MA. A psychomotor stimulant theory of drug addiction. Psychol Rev. 1987;94:469–492[CrossRef][Web of Science][Medline]
  28. Corrigall WA, Franklin KB, Coen KM, Clarke PB. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl). 1992;107:285–289[CrossRef][Medline]
  29. Benwell MEM, Balfour DJK. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br J Pharmacol. 1992;105:849–856[Web of Science][Medline]
  30. Kalivas PW, Sorg BA, Hooks MS. The pharmacology and neural circuitry of sensitization to physicostimulants. Behav Pharmacol. 1993;4:315–334[Web of Science][Medline]
  31. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive sensitization theory of addiction. Brain Res Rev. 1993;18:247–291[CrossRef][Medline]
  32. Benwell MEM, Balfour DJK, Lucchi HM. Influence of tetrodotoxin and calcium on changes in extracellular dopamine levels evoked by systemic nicotine. Psychopharmacology (Berl). 1993;112:467–474[CrossRef][Medline]
  33. Schneider NG. Nicotine therapy in smoking cessation: pharmacokinetic considerations. Clin Pharmacokinet. 1992;23:169–172[Web of Science][Medline]
  34. Benowitz NL, Jacob P, Savanapridi C. Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin Pharmacol Ther. 1987;41:467–473[Web of Science][Medline]
  35. Benwell MEM, Balfour DJK, Anderson JM. Evidence that smoking increases the density of nicotine binding sites in human brain. J Neurochem. 1988;50:1243–1247[Web of Science][Medline]
  36. Malin DH, Lake JR, Carter VA. The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl). 1994;115:180–184[CrossRef][Medline]
  37. Hildebrand BE, Nomikos GG, Hertel P, Schilstrom B, Svensson TH. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res. 1998;779:214–225[CrossRef][Web of Science][Medline]
  38. Benwell MEM, Balfour DJK. Effects of nicotine administration and its withdrawal on plasma corticosterone and brain 5-hydroxyindoles. Psychopharmacology (Berl). 1979;63:7–11[CrossRef][Medline]
  39. Benwell MEM, Balfour DJK. Effects of nicotine administration on the uptake and biosynthesis of 5-HT in rat brain synaptosomes. Eur J Pharmacol. 1982;84:71–77[CrossRef][Web of Science][Medline]
  40. Benwell MEM, Balfour DJK, Anderson JM. Smoking-associated changes in the serotonergic systems of discrete regions of human brain. Psychopharmacology (Berl). 1990;102:68–72[CrossRef][Medline]
  41. Deakin JFW, Graeff FG. 5-HT and mechanisms of defence. J Psychopharmacol. 1991;M5:305–315
  42. Graeff FG, Giumaraes FS, De Andrade TG, Deakin JF. Role of 5-HT in stress, anxiety and depression. Pharmacol Biochem Behav. 1996;5:305–315
  43. Andrews N, Hogg S, Gonzalez LE, File SE. 5-HT1Areceptors in the median raphe nucleus and dorsal hippocampus may mediate anxiolytic and anxiogenic behaviours respectively. Eur J Pharmacol. 1994;264:259–264[CrossRef][Web of Science][Medline]
  44. Silagy, C, Mant, D, Fowler, G, Lancaster, T, Nicotine replacement therapy for smoking cessation
  45. Puska P, Korhonen H, Korhonen T, McAlister A. International Quit & Win '96: a global campaign to promote smoking cessation. Tob Control. 1996;5:342[Medline]
  46. Blöndal T. Controlled trial of nicotine polacrilex gum with supportive measures. Arch Intern Med. 1989;149:1818–1821[Abstract/Free Full Text]
  47. Fagerström KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual vs combined treatment for tobacco withdrawal symptoms. Psychopharmacology (Berl). 1993;111:271–277[CrossRef][Medline]
  48. Jorenby DE, Leischow SJ, Nides MA. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–691[Abstract/Free Full Text]
  49. Jiménez-Ruiz C, Kunze M, Fagerström KO. Nicotine replacement—a new approach to reduce tobacco-related harm. Eur Respir J. 1998;11:473–479[Abstract]
  50. Shiffman S, Gitchell J, Pinney JM, Burton SL, Kemper KE, Lara EA. Public health benefit of over-the-counter nicotine medications. Tob Control. 1997;6:306–310[Abstract]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
Prepared by: British Cardiac Society, British Hype
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Heart, December 1, 2005; 91(suppl_5): v1 - v52.
[Full Text] [PDF]

Home page
 Tobacco ControlHome page
N Gray, J E Henningfield, N L Benowitz, G N Connolly, C Dresler, K Fagerstrom, M J Jarvis, and P Boyle
Toward a comprehensive long term nicotine policy
Tob. Control, June 1, 2005; 14(3): 161 - 165.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
A. B Jessen, S. Toubro, and A. Astrup
Effect of chewing gum containing nicotine and caffeine on energy expenditure and substrate utilization in men
Am. J. Clinical Nutrition, June 1, 2003; 77(6): 1442 - 1447.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme
Eur. Heart J., April 1, 2001; 22(7): 554 - 572.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
G. De Backer and H. Boudrez
Why are smoking cessation strategies not implemented more effectively in clinical practice?
Eur. Heart J., March 2, 2000; 21(6): 434 - 435.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (35)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Balfour, D
Right arrow Articles by Keil, U
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balfour, D
Right arrow Articles by Keil, U
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?